Future innovations in anti-platelet therapies

被引:134
作者
Barrett, N. E. [1 ]
Holbrook, L. [1 ]
Jones, S. [1 ]
Kaiser, W. J. [1 ]
Moraes, L. A. [1 ]
Rana, R. [1 ]
Sage, T. [1 ]
Stanley, R. G. [1 ]
Tucker, K. L. [1 ]
Wright, B. [1 ]
Gibbins, J. M. [1 ]
机构
[1] Univ Reading, Sch Biol Sci, Reading RG6 6AJ, Berks, England
基金
英国医学研究理事会; 英国生物技术与生命科学研究理事会; 英国惠康基金;
关键词
thrombosis; haemostasis; platelets; cardiovascular disease; anti-platelet therapies;
D O I
10.1038/bjp.2008.151
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
Platelets have long been recognized to be of central importance in haemostasis, but their participation in pathological conditions such as thrombosis, atherosclerosis and inflammation is now also well established. The platelet has therefore become a key target in therapies to combat cardiovascular disease. Anti-platelet therapies are used widely, but current approaches lack efficacy in a proportion of patients, and are associated with side effects including problem bleeding. In the last decade, substantial progress has been made in understanding the regulation of platelet function, including the characterization of new ligands, platelet-specific receptors and cell signalling pathways. It is anticipated this progress will impact positively on the future innovations towards more effective and safer anti-platelet agents. In this review, the mechanisms of platelet regulation and current anti-platelet therapies are introduced, and strong, and some more speculative, potential candidate target molecules for future anti-platelet drug development are discussed.
引用
收藏
页码:918 / 939
页数:22
相关论文
共 271 条
[1]
The CC chemokines MDC and TARC induce platelet activation via CCR4 [J].
Abi-Younes, S ;
Si-Tahar, M ;
Luster, AD .
THROMBOSIS RESEARCH, 2001, 101 (04) :279-289
[2]
Disulfide isomerization switches tissue factor from coagulation to cell signaling [J].
Ahamed, Jasimuddin ;
Versteeg, Henri H. ;
Kerver, Marjolein ;
Chen, Vivien M. ;
Mueller, Barbara M. ;
Hogg, Philip J. ;
Ruf, Wolfram .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2006, 103 (38) :13932-13937
[3]
Human bone marrow megakaryocytes and platelets express PPARγ, and PPARγ agonists blunt platelet release of CD40 ligand and thromboxanes [J].
Akbiyik, F ;
Ray, DM ;
Gettings, KF ;
Blumberg, N ;
Francis, CW ;
Phipps, RP .
BLOOD, 2004, 104 (05) :1361-1368
[4]
ENDOCAM - A NOVEL ENDOTHELIAL-CELL CELL-ADHESION MOLECULE [J].
ALBELDA, SM ;
OLIVER, PD ;
ROMER, LH ;
BUCK, CA .
JOURNAL OF CELL BIOLOGY, 1990, 110 (04) :1227-1237
[5]
Role of nuclear receptor signaling in platelets: antithrombotic effects of PPARβ [J].
Ali, Ferhana Y. ;
Davidson, Simon J. ;
Moraes, Leonardo A. ;
Traves, Suzanne L. ;
Paul-Clark, Mark ;
Bishop-Bailey, David ;
Warner, Timothy D. ;
Mitchell, Jane A. .
FASEB JOURNAL, 2006, 20 (02) :326-328
[6]
Class I phosphoinositide 3-kinases [J].
Anderson, KE ;
Jackson, SP .
INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY, 2003, 35 (07) :1028-1033
[7]
P2Y12 regulates platelet adhesion/activation, thrombus growth, and thrombus stability in injured arteries [J].
André, P ;
Delaney, SM ;
LaRocca, T ;
Vincent, D ;
DeGuzman, F ;
Jurek, M ;
Koller, B ;
Phillips, DR ;
Conley, PB .
JOURNAL OF CLINICAL INVESTIGATION, 2003, 112 (03) :398-406
[8]
CD40L stabilizes arterial thrombi by a β3 integrin-dependent mechanism [J].
André, P ;
Prasad, KSS ;
Denis, CV ;
He, M ;
Papalia, JM ;
Hynes, RO ;
Phillips, DR ;
Wagner, DD .
NATURE MEDICINE, 2002, 8 (03) :247-252
[9]
Platelet physiology and thrombosis [J].
Andrews, RK ;
Berndt, MC .
THROMBOSIS RESEARCH, 2004, 114 (5-6) :447-453
[10]
Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy [J].
Angelillo-Scherrer, A ;
Burnier, L ;
Flores, N ;
Savi, P ;
DeMol, M ;
Schaeffer, P ;
Herbert, JM ;
Lemke, G ;
Goff, SP ;
Matsushima, GK ;
Earp, HS ;
Vesin, C ;
Hoylaerts, MF ;
Plaisance, S ;
Collen, D ;
Conway, EM ;
Wehrle-Haller, B ;
Carmeliet, P .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :237-246